1 / 20

Cholangiocarcinoma – What is it? Dr Shahid A Khan Consultant Liver Specialist St Mary's Hospital

Cholangiocarcinoma – What is it? Dr Shahid A Khan Consultant Liver Specialist St Mary's Hospital Imperial College London. AMMF Information Day at Imperial College London 10 th May 2016 St Mary’s Hospital Campus. AMMF Information Day at Imperial College London. Cholangiocarcinoma (CCA)

mfitzgerald
Download Presentation

Cholangiocarcinoma – What is it? Dr Shahid A Khan Consultant Liver Specialist St Mary's Hospital

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cholangiocarcinoma – What is it? Dr Shahid A Khan Consultant Liver SpecialistSt Mary's Hospital Imperial College London AMMF Information Day at Imperial College London 10th May 2016 St Mary’s Hospital Campus

  2. AMMF Information Day at Imperial College London Cholangiocarcinoma (CCA) • What is it? • How many people are affected (epidemiology)? • What causes it? • How is it diagnosed? • What are the unmet needs?

  3. AMMF Information Day at Imperial College London Cholangiocarcinoma (CCA) • What is it? • How many people are affected (epidemiology)? • What causes it? • How is it diagnosed? • What are the unmet needs?

  4. Cholangiocarcinoma (CCA) • Cancer = a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body • Cholangiocarcinoma (CCA) is a cancer of the bile ducts

  5. CCA: Intrahepatic/ Perihilar/ Extrahepatic 50-60% “Perihilar”: arise at bifurcation of main ducts - pCCA 20-30% distal CBD - eCCA 10-20% arise in intrahepatic ducts of liver - iCCA

  6. Cholangiocarcinoma (CCA) • A cancer in a body organ can be primary or secondary • CCA is the second commonest primary liver tumour after Hepatocellular Carcinoma (HCC) • 5-10% all primary liver cancers • Peak age 7thdecade • Slight male preponderance

  7. AMMF Information Day at Imperial College London Cholangiocarcinoma (CCA) • What is it? • How many people are affected (epidemiology)? • What causes it? • How is it diagnosed? • What are the unmet needs?

  8. Epidemiology of CCA: Worldwide Incidence varies, reflecting geographical risk factors & genetic differences

  9. ASMR of all parenchymal tumours, HCC, unspecified tumours and intra + extrahepatic CCA in Men, Eng &Wales, 1968 - 1996 Taylor-Robinson et al., Gut 2001

  10. Studies from around the world show changing trends in Incidence/Mortality of CCA: • Intrahepatic CCA↑ • Extrahepatic CCA↓ • CCA Overall↑ • Since mid-1990’s, iCCA is commonest recorded cause of death from a primary liver tumour in England & Wales, ahead of HCC • Totaldeaths risen 30-fold: 36 in 1968 to > 2100 in 2013 • Large rise in iCCA Age-standardised Mortality Rates (ASMR): males 0.1 to 1.5; females 0.05 to 1.25 • Largest statistical increase in any tumour over this time period • Total deaths from HCC: 472 in 1968 to approx 1500 in 2014

  11. Intrahepatic CCA mortality increased 9% in M & F, 1990-2008, reaching rates of 1.1/100,000 men and 0.75/100,000 women Highest rates in UK, Germany, and France (1.2–1.5/100,000 men, 0.8–1.1/100,000 women) Bertuccio P et al. Ann Oncol 2013

  12. AMMF Information Day at Imperial College London Cholangiocarcinoma (CCA) • What is it? • How many people are affected (epidemiology)? • What causes it? • How is it diagnosed? • What are the unmet needs?

  13. CCA: Causes (Aetiology) & Known Risk Factors • Primary sclerosing cholangitis • Parasitic Infection (Opisthorcis viverrini, Clonorchis sinensis) • Fibropolycystic Liver Disease • Intrahepatic Biliary Stones • Chemical Carcinogen Exposure • Chronic Liver Disease • Viral Hepatitis • Obesity • Type 2 Diabetes >70% of CCA cases in West have NO known risk factors

  14. CCA: Causes (Aetiology) & Known Risk Factors Bergquist et al. 2015 Best Pract Res Clin Gastro

  15. AMMF Information Day at Imperial College London Cholangiocarcinoma (CCA) • What is it? • How many people are affected (epidemiology)? • What causes it? • How is it diagnosed? • What are the unmet needs?

  16. CCA: How is diagnosed? • Symptoms not specific and occur late in the disease process • Discomfort, weight loss, jaundice, itching, sometimes dark urine, pale stool • Imaging • Ultrasound, CT, MRI scans • but the appearances are non-specific • Biopsies (various routes) • Can be difficult due to location • Tumour markers in blood • None are very accurate Hence most CCA cases are diagnosed very late

  17. AMMF Information Day at Imperial College London Cholangiocarcinoma (CCA) • What is it? • How many people are affected (epidemiology)? • What causes it? • How is it diagnosed? • What are the unmet needs?

  18. Unmet Needs and Future (hope) in CCA • Greater awareness of this disease • We need more accurate early diagnostic tools to enable more patients having curative surgery • Need for better 2nd line treatments • Ongoing trials in advanced CCA – chemo; local techniques e.g. ablation • Future hope: CCA treatment will be more individualized, when the genetic profile of a tumor can predict sensitivity or resistance to an agent • 18

  19. Acknowledgments NIHR Biomedical Research Centre Biomedical Research Council (BMRC) Imperial College Healthcare Trustees (donations from Mr. and Mrs. Barry Winter)

  20. Cholangiocarcinoma – What is it? Dr Shahid A Khan Consultant Liver SpecialistSt Mary's Hospital Imperial College London AMMF Information Day at Imperial College London 10th May 2016 St Mary’s Hospital Campus

More Related